Side by side
Follistatin-344 vs Tesamorelin
Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Follistatin-344 | Tesamorelin | |
|---|---|---|
| What it is | A myostatin-blocking protein with dramatic animal results, no human trials, and a serious question over whether what is sold is the real thing. | A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials. |
| EvidenceHow much human evidence exists, not how well it works. | Preclinical | Approved for another indication |
| Regulatory statusReviewed 2026-08-16 | Not approved anywhere, and never studied in a human trial as an injectable protein. Follistatin gene therapy has been studied in small trials for muscular dystrophy. The most advanced pharmaceutical work on the myostatin pathway — using a different molecule — was halted for safety. | Approved by the FDA as a prescription medicine for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for body composition, athletic performance or anti-ageing use, and material sold as a research chemical is not the approved product. |
| Routes | Subcutaneous, Intramuscular | Subcutaneous |
| Half-life | Not recorded | 0.4 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $0.44/mg | $2.35/mg |
| Median per mg | $138.50/mg | $6.50/mg |
| Vendors with a price | 10 | 49 |
| Storage once mixed | Refrigerated at 2–8 °C, and used quickly. A large glycoprotein is far less stable in solution than a short peptide, and it will not look any different once it has lost activity. | Refrigerated at 2–8 °C. The approved product is intended for use shortly after reconstitution rather than stored for weeks. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.